UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus ... GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin).
Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by widespread vascular abnormalities, immune system activation, and skin and internal ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Alzheimer’s disease and multiple sclerosis. Systemic lupus erythematosus (SLE) is an autoimmune disease that sometimes involves the central nervous system in a condition known as ...
A new study finds that patients with systemic sclerosis (SSc) have a significantly higher risk of cancer-related mortality, ...
Discover how nintedanib effectively slows lung function decline in systemic sclerosis-associated interstitial lung disease, ...
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
Potential therapeutic targets to address monocyte and macrophage involvement in IIMs include anti-CCR2, anti-GM-CSF, anti-CSF-1R, Nrf2 activators, PPAR-γ agonists, mesenchymal stem cell-derived ...
Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback